US Gastroenterologis
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
November 13, 2023 09:22 ET | Spherix Global Insights
Exton, Pennsylvania, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by the...
Mordor Intelligence Logo_Comp.png
Short-Acting Insulin Market Revenues to Reach USD 8.29 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 18, 2023 09:30 ET | Mordor Intelligence
Hyderabad, Aug. 18, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Short-Acting Insulin Market Report (2023-2028)," the market is estimated at USD 6.99 billion in 2023....
Mordor Intelligence Logo_Comp.png
Mexico Insulin Drugs and Delivery Devices Market Revenues to Reach USD 566.91 million by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 09, 2023 09:30 ET | Mordor Intelligence
Hyderabad, Aug. 09, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Mexico Insulin Drugs and Delivery Devices Market Report (2023-2028)," the market is estimated at USD...
Pfizer’s Litfulo Poi
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
July 11, 2023 09:58 ET | Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Mordor Intelligence Logo_Comp.png
Middle East and Africa Human Insulin Market is anticipated to register a CAGR of greater than 4% during 2023 – 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
April 05, 2023 09:00 ET | Mordor Intelligence
Hyderabad, April 05, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Middle East and Africa Human Insulin Market - (2023 – 2028),” the market is expected to register a...
IpiNovyx Logo.jpg
IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies
October 05, 2021 07:00 ET | IpiNovyx
Participating Investors include Viva BioInnovator, Eli Lilly and Company, Opaleye Management, Orange Grove Bio and Alexandria Venture Investments Foundational Science Stems From Landmark Research at...
logo-alt.png
Global Schizophrenia Drug Market is estimated to be US$ 9.8 Bn by 2030 with a CAGR of 2.7% during the forecast period - by PMI
February 24, 2021 10:05 ET | PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The global schizophrenia drug market accounted for US$ 7.5 Bn in 2020 and is estimated to be US$ 9.8 Bn by 2030 and is anticipated to register a CAGR of...
logo-alt.png
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 12, 2021 10:05 ET | PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
December 16, 2020 14:56 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches...
BES_Mark.jpg
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
December 16, 2020 12:37 ET | Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...